Serengulam V. Govindan

Author

Also Known As

Govindan, Suresh, S Govindan, S V Govindan, S. GOVINDAN, S. Govindan, S. V. GOVINDAN, S. V. Govindan, S.V. Govindan, Serengulam Govindan, Serengulam V Govindan

204

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

Immunomedics (United States)Center for Molecular Medicine and Immunology Cornell University Immunomedics (Germany)University of Colorado Denver

About

Serengulam V. Govindan is an author at Immunomedics (United States) specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	1.8K
2	Natural Sciences	4	4	109
3	Engineering	3	3	159
4	Health Sciences	3	3	76
5	Allergy	1	1	31

Serengulam V. Govindan

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan, Oncotarget	2015	447
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, Journal of Clinical Oncology Breast OncologyMedicineAntibody-drug ConjugateCancer ManagementImmunology	2017	386
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Clinical Cancer Research	2015	341
Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Clinical Cancer Research	2011	285
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Bioconjugate Chemistry Anti-trop-2/sn-38 Antibody–drug ConjugateImmunologyImmunoeditingPathologyOther Cancers	2015	280
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics Allyson J. Ocean, Alexander Starodub, Aditya Bardia, Cancer	2017	227
Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters, Journal of Clinical Oncology	2017	181
Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys Puja Sapra, Rhona Stein, J. Pickett, Clinical Cancer Research	2005	168
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan) Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Clinical Cancer Research	2015	161
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub, Clinical Cancer Research	2017	155

Page 1